1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Innate Inflammatory Response in 98 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine if the beneficial effects of transient desflurane application mitigates inflammation and decrease associated signaling induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in mice." | 8.12 | Beneficial effect of transient desflurane inhalation on relieving inflammation and reducing signaling induced by MPTP in mice. ( Ge, Z; Li, W; Qin, G; Yu, Z, 2022) |
| " Specifically, we aimed to explore the mechanism by which puerarin prevents inflammation and apoptosis in neurocytes." | 7.83 | Puerarin prevents inflammation and apoptosis in the neurocytes of a murine Parkinson's disease model. ( Gao, Y; Jiang, M; Niu, G; Shi, F; Yu, S; Yun, Q, 2016) |
| "Neuroinflammation is one of the critical pathological mechanisms influencing various neurodegenerative disorders." | 5.42 | Anti-neuroinflammatory effects of DPTP, a novel synthetic clovamide derivative in in vitro and in vivo model of neuroinflammation. ( Choi, DK; Jeon, SB; Kim, BW; Lim, HW; More, SV; Park, EJ; Park, JI; Park, JY; Yoon, SH; Yun, YS, 2015) |
| "Neuroinflammation is thought to be one of the major pathological mechanisms responsible for Parkinson's disease (PD), and has been a primary target in the development of treatment for PD." | 5.38 | Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo. ( Ha, SK; Ju, MS; Kim, HG; Kim, SY; Lee, H; Oh, MS, 2012) |
| "Treatment with paroxetine prevented degeneration of nigrostriatal DA neurons, increased striatal dopamine levels, and improved motor function." | 5.36 | Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. ( Chung, YC; Jin, BK; Kim, SR, 2010) |
| "Treatment of melatonin with MPTP reversed all these MPTP-induced changes." | 5.36 | The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6. ( Nath, C; Niranjan, R; Shukla, R, 2010) |
| " Using a chronic regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid (MPTP/p) in mice, dopamine cell loss exceeds 60%, extracellular glutamate is elevated, cytoplasmic inclusions are formed and inflammation is chronic." | 4.84 | Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. ( Meredith, GE; Potashkin, JA; Surmeier, DJ; Totterdell, S, 2008) |
| "To determine if the beneficial effects of transient desflurane application mitigates inflammation and decrease associated signaling induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in mice." | 4.12 | Beneficial effect of transient desflurane inhalation on relieving inflammation and reducing signaling induced by MPTP in mice. ( Ge, Z; Li, W; Qin, G; Yu, Z, 2022) |
| " Then, in mouse models, we assessed whether dextran sodium sulfate-mediated colitis could exert lingering effects on dopaminergic pathways in the brain and whether colitis increased vulnerability to a subsequent exposure to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 4.02 | Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology. ( Caudle, WM; Chang, J; Houser, MC; Joers, V; Kannarkat, GT; Kelly, SD; Keshavarzian, A; Oliver, D; Shannon, KM; Tansey, MG; Yang, Y, 2021) |
| "We demonstrate that Eupatilin alleviates behavioral impairment and dopaminergic neuron loss induced by MPTP through inhibition of neuroinflammation and apoptosis." | 3.96 | Eupatilin prevents behavioral deficits and dopaminergic neuron degeneration in a Parkinson's disease mouse model. ( Li, J; Qin, L; Wang, C; Xie, J; Zhang, Y, 2020) |
| " In our previous study, we have shown that brain-specific microRNA-124 (miR-124) is significantly down-regulated in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD and that it can also inhibit neuroinflammation during the development of PD." | 3.91 | MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson's disease. ( Lu, G; Qian, C; Sun, X; Wang, B; Wu, J; Xie, L; Yao, L; Zhang, H; Zhang, S; Zhang, Y; Zhu, Z, 2019) |
| "The present study is to investigate the neuroprotective effect of ibuprofen by intranasal administration of mucoadhesive microemulsion (MMEI) against inflammation-mediated by dopaminergic neurodegeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease (PD)." | 3.83 | Design and evaluation of mucoadhesive microemulsion for neuroprotective effect of ibuprofen following intranasal route in the MPTP mice model. ( Chuttani, K; Mandal, S; Mandal, SD; Sawant, KK; Subudhi, BB, 2016) |
| " Specifically, we aimed to explore the mechanism by which puerarin prevents inflammation and apoptosis in neurocytes." | 3.83 | Puerarin prevents inflammation and apoptosis in the neurocytes of a murine Parkinson's disease model. ( Gao, Y; Jiang, M; Niu, G; Shi, F; Yu, S; Yun, Q, 2016) |
| "Current evidence suggests a role of neuroinflammation in the pathogenesis of Parkinson's disease (PD) and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of basal ganglia injury." | 3.76 | Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. ( Caniglia, S; Impagnatiello, F; L'Episcopo, F; Marchetti, B; Morale, MC; Serra, PA; Testa, N; Tirolo, C, 2010) |
| "Inflammasome involvement in Parkinson's disease (PD) has been intensively investigated." | 1.72 | Microglial AIM2 alleviates antiviral-related neuro-inflammation in mouse models of Parkinson's disease. ( Fan, Y; Hu, YC; Li, S; Liu, Y; Ma, CM; Rui, WJ; Shi, JP; Wang, BW; Yang, L, 2022) |
| "Prucalopride treatment also ameliorated intestinal barrier impairment and increased IL-6 release in PD model mice." | 1.62 | Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier. ( Cui, C; Hong, H; Huang, SB; Jia, XB; Qiao, CM; Shen, YQ; Shi, Y; Wu, J; Yao, L; Zhao, WJ; Zhou, Y, 2021) |
| "Simvastatin can play a positive role in Parkinson's disease." | 1.56 | Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice. ( Fan, H; Huang, J; Lai, X; Liu, A; Qiao, L; Shen, M; Wu, J; Yan, J, 2020) |
| "Neuroinflammation is one of the hallmarks of neurodegenerative diseases, such as Parkinson's disease (PD)." | 1.48 | The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor. ( Boyle, AM; Budge, KM; Neal, ML; Richardson, JR; Safadi, FF, 2018) |
| "Amplified inflammation is important for the progression of Parkinson's disease (PD)." | 1.48 | JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss. ( Chen, Y; He, Q; Shao, W; Wang, Q; Wang, Y; Yuan, C, 2018) |
| "Patients with Parkinson's disease (PD) often have non-motor symptoms related to gastrointestinal (GI) dysfunction, such as constipation and delayed gastric emptying, which manifest prior to the motor symptoms of PD." | 1.48 | Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease. ( Bai, Q; Gao, J; Jia, Y; Jiang, R; Lai, F; Liu, X; Tang, Y; Xiao, H; Xie, W, 2018) |
| "Although the initial events of sporadic Parkinson's disease (PD) are not known, consistent evidence supports the hypothesis that the disease results from the combined effect of genetic and environmental risk factors." | 1.43 | Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson's disease. ( Di Meco, A; Lauretti, E; Merali, S; Praticò, D, 2016) |
| "Neuroinflammation is implicated for dopaminergic neurodegeneration." | 1.43 | Inhibitory effect of thiacremonone on MPTP-induced dopaminergic neurodegeneration through inhibition of p38 activation. ( Choi, DY; Han, SB; Hong, JT; Hwang, CJ; Hwang, DY; Jeong, HS; Kim, SY; Kim, TH; Kim, YM; Lee, HJ; Lee, HP; Lee, TH; Moon, DB; Oh, KW; Park, SS, 2016) |
| "Neuroinflammation is one of the critical pathological mechanisms influencing various neurodegenerative disorders." | 1.42 | Anti-neuroinflammatory effects of DPTP, a novel synthetic clovamide derivative in in vitro and in vivo model of neuroinflammation. ( Choi, DK; Jeon, SB; Kim, BW; Lim, HW; More, SV; Park, EJ; Park, JI; Park, JY; Yoon, SH; Yun, YS, 2015) |
| "Phytic acid (PA) is a naturally occurring constituent which exhibits protective action in Parkinson's disease (PD)." | 1.42 | Phytic acid attenuates inflammatory responses and the levels of NF-κB and p-ERK in MPTP-induced Parkinson's disease model of mice. ( Gai, X; Hou, L; Liu, C; Liu, L; Lu, T; Lv, Y; Wang, Y; Xu, P; Zhang, J; Zhang, L; Zhang, Z, 2015) |
| "Chronic neuroinflammation is a common feature of the ageing brain and some neurodegenerative disorders." | 1.39 | Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallin. ( Chen, T; Hu, G; Huang, YY; Li, SB; Liu, YJ; Shao, W; Tang, M; Wawrousek, E; Xu, M; Yin, YQ; Zhang, SZ; Zhang, XH; Zhou, JN; Zhou, JW; Zhou, QB; Zhou, Z, 2013) |
| "Neuroinflammation is thought to be one of the major pathological mechanisms responsible for Parkinson's disease (PD), and has been a primary target in the development of treatment for PD." | 1.38 | Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo. ( Ha, SK; Ju, MS; Kim, HG; Kim, SY; Lee, H; Oh, MS, 2012) |
| "In a mouse model of MPTP-induced Parkinson's disease (PD), AQP4-deficient animals show more robust microglial inflammatory responses and more severe loss of dopaminergic neurons (DNs) compared with WT mice." | 1.37 | Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease. ( Chi, Y; Fan, Y; He, L; Hu, G; Kong, H; Li, CJ; Liu, W; Sonoda, L; Su, C; Tripathi, P; Wang, X; Wen, X; Yu, MS; Zhang, C; Zhou, S, 2011) |
| "Neuroinflammation is implicated in the progression of numerous disease states of the CNS, but early inflammatory signaling events in glial cells that may predispose neurons to injury are not easily characterized in vivo." | 1.37 | Low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor-κB reporter mice prior to loss of dopaminergic neurons. ( Bialecki, RA; Miller, JA; Roberts, RA; Sullivan, KA; Tjalkens, RB; Trout, BR, 2011) |
| "Treatment with paroxetine prevented degeneration of nigrostriatal DA neurons, increased striatal dopamine levels, and improved motor function." | 1.36 | Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. ( Chung, YC; Jin, BK; Kim, SR, 2010) |
| "Treatment of melatonin with MPTP reversed all these MPTP-induced changes." | 1.36 | The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6. ( Nath, C; Niranjan, R; Shukla, R, 2010) |
| "Neuroinflammation is a hot topic in contemporary neuroscience." | 1.35 | Defining "neuroinflammation". ( Miller, DB; O'Callaghan, JP; Sriram, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (15.31) | 29.6817 |
| 2010's | 45 (45.92) | 24.3611 |
| 2020's | 38 (38.78) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, C | 3 |
| Hong, H | 2 |
| Shi, Y | 3 |
| Zhou, Y | 5 |
| Qiao, CM | 3 |
| Zhao, WJ | 2 |
| Zhao, LP | 2 |
| Wu, J | 5 |
| Quan, W | 1 |
| Niu, GY | 1 |
| Wu, YB | 1 |
| Li, CS | 1 |
| Cheng, L | 1 |
| Hong, Y | 1 |
| Shen, YQ | 3 |
| Liu, N | 2 |
| Bai, L | 1 |
| Lu, Z | 1 |
| Gu, R | 1 |
| Zhao, D | 1 |
| Yan, F | 1 |
| Bai, J | 1 |
| Sun, X | 3 |
| Zhang, C | 2 |
| Tao, H | 1 |
| Yao, S | 1 |
| Wu, X | 2 |
| Morissette, M | 1 |
| Bourque, M | 1 |
| Tremblay, MÈ | 1 |
| Di Paolo, T | 1 |
| Su, Y | 1 |
| Zhang, Z | 5 |
| Li, H | 1 |
| Ma, J | 1 |
| Yuan, Y | 2 |
| Shi, M | 2 |
| Liu, J | 1 |
| Zhao, Z | 1 |
| Holscher, C | 3 |
| Dutta, A | 1 |
| Phukan, BC | 1 |
| Roy, R | 1 |
| Mazumder, MK | 1 |
| Paul, R | 1 |
| Choudhury, A | 1 |
| Kumar, D | 1 |
| Bhattacharya, P | 1 |
| Nath, J | 1 |
| Kumar, S | 1 |
| Borah, A | 1 |
| Yu, Z | 2 |
| Qin, G | 1 |
| Ge, Z | 1 |
| Li, W | 1 |
| Wu, Y | 2 |
| Liu, H | 1 |
| Wang, Y | 7 |
| Sheng, H | 1 |
| Chen, Z | 1 |
| Xun, D | 1 |
| Wu, H | 1 |
| Xiao, S | 1 |
| Bi, Y | 1 |
| Rui, WJ | 1 |
| Li, S | 2 |
| Yang, L | 1 |
| Liu, Y | 3 |
| Fan, Y | 2 |
| Hu, YC | 1 |
| Ma, CM | 1 |
| Wang, BW | 1 |
| Shi, JP | 1 |
| He, D | 1 |
| Li, J | 2 |
| Wang, H | 1 |
| Ye, B | 1 |
| He, Y | 1 |
| Li, Z | 1 |
| Gao, X | 1 |
| Fu, S | 1 |
| Liu, D | 1 |
| Liu, X | 3 |
| Ye, Q | 1 |
| Zhang, J | 5 |
| Lin, S | 1 |
| Wang, G | 1 |
| Yang, X | 1 |
| Chen, S | 1 |
| Wu, N | 1 |
| Kartik, S | 1 |
| Pal, R | 1 |
| Chaudhary, MJ | 1 |
| Nath, R | 1 |
| Kumar, M | 1 |
| Binwal, M | 1 |
| Bawankule, DU | 1 |
| Lee, YR | 1 |
| Moon, GH | 1 |
| Shim, D | 1 |
| Kim, JC | 1 |
| Lee, KJ | 1 |
| Chung, KH | 1 |
| An, JH | 1 |
| Chiu, YJ | 1 |
| Lin, CH | 1 |
| Lin, CY | 1 |
| Yang, PN | 1 |
| Lo, YS | 1 |
| Chen, YC | 1 |
| Chen, CM | 1 |
| Wu, YR | 1 |
| Yao, CF | 1 |
| Chang, KH | 1 |
| Lee-Chen, GJ | 1 |
| Jiang, W | 1 |
| Cheng, Y | 1 |
| Rong, Z | 1 |
| Sun, L | 1 |
| Zhang, K | 1 |
| Leem, YH | 1 |
| Kim, DY | 1 |
| Park, JE | 1 |
| Kim, HS | 1 |
| Meng, HW | 1 |
| Shen, ZB | 1 |
| Meng, XS | 1 |
| Yin, ZQ | 1 |
| Wang, XR | 1 |
| Zou, TF | 1 |
| Liu, ZG | 1 |
| Wang, TX | 1 |
| Zhang, S | 3 |
| Chen, YL | 1 |
| Yang, XX | 1 |
| Li, QS | 1 |
| Duan, YJ | 1 |
| Pu, Z | 2 |
| Liu, S | 2 |
| Guo, Z | 1 |
| Zhang, X | 4 |
| Yan, J | 2 |
| Tang, Y | 3 |
| Xiao, H | 3 |
| Gao, J | 3 |
| Li, Y | 3 |
| Bai, Q | 3 |
| Guo, X | 2 |
| Wang, Q | 3 |
| Sheng, X | 1 |
| Zheng, L | 1 |
| Mei, M | 1 |
| Liu, M | 1 |
| Zhao, F | 1 |
| Wang, C | 2 |
| Ding, J | 1 |
| Lu, M | 1 |
| Hu, G | 4 |
| Xue, B | 1 |
| Xiao, W | 1 |
| Tian, H | 1 |
| Liu, A | 1 |
| Fan, H | 1 |
| Qiao, L | 1 |
| Shen, M | 1 |
| Lai, X | 1 |
| Huang, J | 2 |
| Liu, Q | 1 |
| Huang, Z | 1 |
| He, Q | 2 |
| Zhu, D | 1 |
| Peng, Z | 1 |
| Che, Y | 1 |
| Feng, X | 1 |
| Liu, WW | 1 |
| Wei, SZ | 1 |
| Huang, GD | 1 |
| Liu, LB | 1 |
| Gu, C | 1 |
| Shen, Y | 1 |
| Wang, XH | 1 |
| Xia, ST | 1 |
| Xie, AM | 1 |
| Hu, LF | 1 |
| Wang, F | 2 |
| Liu, CF | 1 |
| Yang, Y | 2 |
| Kong, F | 1 |
| Ding, Q | 1 |
| Cai, Y | 1 |
| Hao, Y | 1 |
| Tang, B | 1 |
| Zhang, Y | 6 |
| Qin, L | 1 |
| Xie, J | 1 |
| Sun, MF | 1 |
| Jia, XB | 2 |
| Zhang, BP | 1 |
| Zhou, ZL | 1 |
| Zhu, YL | 1 |
| Cai, LJ | 1 |
| Tu, L | 1 |
| Huang, XM | 1 |
| Qiu, N | 1 |
| Xie, GH | 1 |
| Liao, JX | 1 |
| Du, W | 1 |
| Zhang, YY | 1 |
| Tian, JY | 1 |
| Jeon, H | 2 |
| Kim, HY | 2 |
| Bae, CH | 2 |
| Lee, Y | 2 |
| Kim, S | 2 |
| Song, SY | 1 |
| Kim, IS | 1 |
| Koppula, S | 1 |
| Park, JY | 2 |
| Kim, BW | 2 |
| Yoon, SH | 2 |
| Choi, DK | 2 |
| Ou, Z | 1 |
| Wang, L | 3 |
| Xue, L | 2 |
| Zheng, J | 2 |
| Chen, L | 2 |
| Tong, Q | 2 |
| Wu, WJ | 1 |
| Lu, CW | 1 |
| Wang, SE | 1 |
| Lin, CL | 1 |
| Su, LY | 1 |
| Wu, CH | 1 |
| Hao, L | 1 |
| Shao, S | 1 |
| Yin, Q | 1 |
| Jia, Y | 2 |
| Huang, SB | 1 |
| Yao, L | 2 |
| Wang, X | 2 |
| Liu, Z | 1 |
| Cuenca-Bermejo, L | 1 |
| Pizzichini, E | 1 |
| Gonçalves, VC | 1 |
| Guillén-Díaz, M | 1 |
| Aguilar-Moñino, E | 1 |
| Sánchez-Rodrigo, C | 1 |
| González-Cuello, AM | 1 |
| Fernández-Villalba, E | 1 |
| Herrero, MT | 2 |
| Houser, MC | 1 |
| Caudle, WM | 1 |
| Chang, J | 1 |
| Kannarkat, GT | 1 |
| Kelly, SD | 1 |
| Oliver, D | 1 |
| Joers, V | 1 |
| Shannon, KM | 1 |
| Keshavarzian, A | 1 |
| Tansey, MG | 1 |
| Yuan, Z | 1 |
| Li, D | 1 |
| Feng, P | 1 |
| Xue, G | 1 |
| Ji, C | 1 |
| Li, G | 1 |
| Ren, M | 1 |
| Guo, Y | 1 |
| Wei, X | 1 |
| Yan, S | 1 |
| Qin, Y | 1 |
| Jiang, F | 1 |
| Lou, H | 1 |
| Neal, ML | 1 |
| Boyle, AM | 1 |
| Budge, KM | 1 |
| Safadi, FF | 1 |
| Richardson, JR | 1 |
| L'Episcopo, F | 3 |
| Tirolo, C | 3 |
| Peruzzotti-Jametti, L | 1 |
| Serapide, MF | 1 |
| Testa, N | 3 |
| Caniglia, S | 3 |
| Balzarotti, B | 1 |
| Pluchino, S | 1 |
| Marchetti, B | 3 |
| Feng, S | 1 |
| Nie, K | 1 |
| Gao, Y | 2 |
| Gan, R | 1 |
| Li, B | 1 |
| Rosa, AI | 1 |
| Duarte-Silva, S | 1 |
| Silva-Fernandes, A | 1 |
| Nunes, MJ | 1 |
| Carvalho, AN | 1 |
| Rodrigues, E | 1 |
| Gama, MJ | 1 |
| Rodrigues, CMP | 1 |
| Maciel, P | 1 |
| Castro-Caldas, M | 1 |
| Cordaro, M | 1 |
| Siracusa, R | 2 |
| Crupi, R | 1 |
| Impellizzeri, D | 1 |
| Peritore, AF | 1 |
| D'Amico, R | 1 |
| Gugliandolo, E | 1 |
| Di Paola, R | 1 |
| Cuzzocrea, S | 2 |
| Tian, X | 1 |
| Chen, Y | 1 |
| Shao, W | 2 |
| Yuan, C | 1 |
| Lai, F | 1 |
| Jiang, R | 1 |
| Xie, W | 1 |
| Singh, K | 1 |
| Han, K | 1 |
| Tilve, S | 1 |
| Wu, K | 1 |
| Geller, HM | 1 |
| Sack, MN | 1 |
| Yang, J | 1 |
| Jia, M | 1 |
| Wang, P | 1 |
| Campolo, M | 1 |
| Paterniti, I | 1 |
| Filippone, A | 1 |
| Esposito, E | 1 |
| Xue, X | 1 |
| Zhang, W | 1 |
| Zhu, J | 1 |
| Chen, X | 1 |
| Zhou, S | 2 |
| Xu, Z | 1 |
| Su, C | 2 |
| Zhu, Z | 1 |
| Zhang, H | 1 |
| Qian, C | 1 |
| Wang, B | 1 |
| Xie, L | 1 |
| Lu, G | 1 |
| Rai, SN | 1 |
| Zahra, W | 1 |
| Singh, SS | 1 |
| Birla, H | 1 |
| Keswani, C | 1 |
| Dilnashin, H | 1 |
| Rathore, AS | 1 |
| Singh, R | 1 |
| Singh, RK | 1 |
| Singh, SP | 1 |
| Oikawa, S | 1 |
| Kai, Y | 1 |
| Mano, A | 1 |
| Sugama, S | 1 |
| Mizoguchi, N | 1 |
| Tsuda, M | 1 |
| Muramoto, K | 1 |
| Kakinuma, Y | 1 |
| González, H | 1 |
| Contreras, F | 1 |
| Prado, C | 1 |
| Elgueta, D | 1 |
| Franz, D | 1 |
| Bernales, S | 1 |
| Pacheco, R | 1 |
| Tristão, FS | 1 |
| Amar, M | 1 |
| Latrous, I | 1 |
| Del-Bel, EA | 1 |
| Prediger, RD | 1 |
| Raisman-Vozari, R | 1 |
| Johansson, JU | 1 |
| Pradhan, S | 1 |
| Lokteva, LA | 1 |
| Woodling, NS | 1 |
| Ko, N | 1 |
| Brown, HD | 1 |
| Loh, C | 1 |
| Cekanaviciute, E | 1 |
| Buckwalter, M | 1 |
| Manning-Bog, AB | 1 |
| Andreasson, KI | 1 |
| Lim, HW | 1 |
| Park, JI | 1 |
| More, SV | 1 |
| Jeon, SB | 1 |
| Yun, YS | 1 |
| Park, EJ | 1 |
| Anitua, E | 1 |
| Pascual, C | 1 |
| Pérez-Gonzalez, R | 1 |
| Orive, G | 1 |
| Carro, E | 1 |
| Stojkovska, I | 1 |
| Wagner, BM | 1 |
| Morrison, BE | 1 |
| Lv, Y | 1 |
| Hou, L | 1 |
| Zhang, L | 1 |
| Liu, C | 1 |
| Xu, P | 2 |
| Liu, L | 1 |
| Gai, X | 1 |
| Lu, T | 1 |
| Sconce, MD | 1 |
| Churchill, MJ | 1 |
| Greene, RE | 1 |
| Meshul, CK | 1 |
| Muñoz-Manchado, AB | 1 |
| Villadiego, J | 1 |
| Romo-Madero, S | 1 |
| Suárez-Luna, N | 1 |
| Bermejo-Navas, A | 1 |
| Rodríguez-Gómez, JA | 1 |
| Garrido-Gil, P | 2 |
| Labandeira-García, JL | 1 |
| Echevarría, M | 1 |
| López-Barneo, J | 1 |
| Toledo-Aral, JJ | 1 |
| Mandal, S | 1 |
| Mandal, SD | 1 |
| Chuttani, K | 1 |
| Sawant, KK | 1 |
| Subudhi, BB | 1 |
| Heng, Y | 1 |
| Zhang, QS | 1 |
| Mu, Z | 1 |
| Hu, JF | 1 |
| Yuan, YH | 1 |
| Chen, NH | 1 |
| Mitra, S | 1 |
| Ghosh, N | 1 |
| Sinha, P | 1 |
| Chakrabarti, N | 1 |
| Bhattacharyya, A | 1 |
| Lauretti, E | 1 |
| Di Meco, A | 1 |
| Merali, S | 1 |
| Praticò, D | 1 |
| Giacoppo, S | 1 |
| Rajan, TS | 1 |
| De Nicola, GR | 1 |
| Iori, R | 1 |
| Rollin, P | 1 |
| Bramanti, P | 1 |
| Mazzon, E | 1 |
| Hwang, CJ | 1 |
| Lee, HP | 1 |
| Choi, DY | 1 |
| Jeong, HS | 1 |
| Kim, TH | 1 |
| Lee, TH | 1 |
| Kim, YM | 1 |
| Moon, DB | 1 |
| Park, SS | 1 |
| Kim, SY | 2 |
| Oh, KW | 1 |
| Hwang, DY | 1 |
| Han, SB | 1 |
| Lee, HJ | 1 |
| Hong, JT | 1 |
| Jiang, M | 1 |
| Yun, Q | 1 |
| Niu, G | 1 |
| Shi, F | 1 |
| Yu, S | 2 |
| Lee, JH | 1 |
| Chung, YC | 2 |
| Bok, E | 1 |
| Lee, H | 3 |
| Huh, SH | 1 |
| Lee, JE | 1 |
| Jin, BK | 2 |
| Ko, HW | 1 |
| Stayte, S | 1 |
| Rentsch, P | 1 |
| Tröscher, AR | 1 |
| Bamberger, M | 1 |
| Li, KM | 1 |
| Vissel, B | 1 |
| He, X | 1 |
| Lei, M | 1 |
| Wei, Z | 1 |
| Wen, L | 1 |
| Qu, S | 1 |
| Meredith, GE | 1 |
| Totterdell, S | 1 |
| Potashkin, JA | 1 |
| Surmeier, DJ | 1 |
| O'Callaghan, JP | 1 |
| Sriram, K | 1 |
| Miller, DB | 1 |
| Kurkowska-Jastrzebska, I | 2 |
| Bałkowiec-Iskra, E | 1 |
| Ciesielska, A | 2 |
| Joniec, I | 2 |
| Cudna, A | 1 |
| Zaremba, MM | 1 |
| Członkowski, A | 2 |
| Członkowska, A | 2 |
| De Pablos, V | 1 |
| Barcia, C | 1 |
| Martínez, S | 1 |
| Gomez, A | 1 |
| Ros-Bernal, F | 1 |
| Zamarro-Parra, J | 1 |
| Soria-Torrecillas, JJ | 1 |
| Hernández, J | 1 |
| Ceron, JJ | 1 |
| Vázquez-Claverie, M | 1 |
| San Sebastián, W | 1 |
| Izal-Azcárate, A | 1 |
| Belzunegui, S | 1 |
| Marcilla, I | 1 |
| López, B | 1 |
| Luquin, MR | 1 |
| Kim, SR | 1 |
| Niranjan, R | 1 |
| Nath, C | 1 |
| Shukla, R | 1 |
| Serra, PA | 2 |
| Impagnatiello, F | 1 |
| Morale, MC | 2 |
| Chi, Y | 1 |
| He, L | 1 |
| Liu, W | 1 |
| Wen, X | 1 |
| Kong, H | 1 |
| Sonoda, L | 1 |
| Tripathi, P | 1 |
| Li, CJ | 1 |
| Yu, MS | 1 |
| Miller, JA | 1 |
| Trout, BR | 1 |
| Sullivan, KA | 1 |
| Bialecki, RA | 1 |
| Roberts, RA | 1 |
| Tjalkens, RB | 1 |
| Kim, HG | 1 |
| Ju, MS | 1 |
| Ha, SK | 1 |
| Oh, MS | 1 |
| Martens, LH | 1 |
| Barmada, SJ | 1 |
| Zhou, P | 1 |
| Kamiya, S | 1 |
| Sun, B | 1 |
| Min, SW | 1 |
| Gan, L | 1 |
| Finkbeiner, S | 1 |
| Huang, EJ | 1 |
| Farese, RV | 1 |
| Zhang, SZ | 1 |
| Tang, M | 1 |
| Zhang, XH | 1 |
| Zhou, Z | 1 |
| Yin, YQ | 1 |
| Zhou, QB | 1 |
| Huang, YY | 1 |
| Liu, YJ | 1 |
| Wawrousek, E | 1 |
| Chen, T | 1 |
| Li, SB | 1 |
| Xu, M | 1 |
| Zhou, JN | 1 |
| Zhou, JW | 1 |
| Eberhardt, O | 1 |
| Schulz, JB | 1 |
| Goralski, KB | 1 |
| Renton, KW | 1 |
| Litwin, T | 1 |
| Przybyłkowski, A | 1 |
| Bibbiani, F | 1 |
| Costantini, LC | 1 |
| Patel, R | 1 |
| Chase, TN | 1 |
| Miklossy, J | 1 |
| Doudet, DD | 1 |
| Schwab, C | 1 |
| McGeer, EG | 2 |
| McGeer, PL | 2 |
| Gennuso, F | 1 |
| Giaquinta, G | 1 |
| Rocchitta, G | 1 |
| Desole, MS | 1 |
| Miele, E | 1 |
| Hald, A | 1 |
| Van Beek, J | 1 |
| Lotharius, J | 1 |
| Miller, RL | 1 |
| James-Kracke, M | 1 |
| Sun, GY | 1 |
| Sun, AY | 1 |
| Björklund, A | 1 |
| Kirik, D | 1 |
| Rosenblad, C | 1 |
| Georgievska, B | 1 |
| Lundberg, C | 1 |
| Mandel, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Leukine (Sargramostim) for Parkinson's Disease[NCT01882010] | Phase 1 | 37 participants (Actual) | Interventional | 2013-09-01 | Completed | ||
| A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease[NCT01621581] | Phase 1 | 25 participants (Actual) | Interventional | 2013-03-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Innate Inflammatory Response
| Article | Year |
|---|---|
Parkinson's disease and enhanced inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyto | 2015 |
Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Disease Models, Animal; Dopamine; | 2008 |
Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspases; Cell Cycle; Inflammation | 2003 |
Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Humans; In | 2006 |
Inflammation in Parkinson's disease: causative or epiphenomenal?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disea | 2007 |
Glial reactions in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents, No | 2008 |
Oxidative and inflammatory pathways in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Herbicides; Humans; Inflammation; Lipopolysac | 2009 |
Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Cell Survival; Corpus Striatum; | 2000 |
90 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Innate Inflammatory Response
| Article | Year |
|---|---|
Vancomycin Pretreatment on MPTP-Induced Parkinson's Disease Mice Exerts Neuroprotection by Suppressing Inflammation Both in Brain and Gut.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Infl | 2023 |
TRPV4 contributes to ER stress and inflammation: implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
LINC00943 acts as miR-338-3p sponge to promote MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell | 2022 |
Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dyskinesia, Drug-Induced; Humans; Infl | 2022 |
Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cholecystokinin; Colon; Dise | 2022 |
Garcinia morella extract confers dopaminergic neuroprotection by mitigating mitochondrial dysfunctions and inflammation in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2022 |
Beneficial effect of transient desflurane inhalation on relieving inflammation and reducing signaling induced by MPTP in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Desflurane; Disease Models, Animal; Glial Fib | 2022 |
DiHuangYin decoction protects dopaminergic neurons in a Parkinson's disease model by alleviating peripheral inflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Microglial AIM2 alleviates antiviral-related neuro-inflammation in mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiviral Agents; Disease Models, Animal; DNA | 2022 |
Isoalantolactone (IAL) Regulates Neuro-Inflammation and Neuronal Apoptosis to Curb Pathology of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Infla | 2022 |
Fucosylated Chondroitin Sulfate against Parkinson's Disease through Inhibiting Inflammation Induced by Gut Dysbiosis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Chondroitin Sulfates; Diseas | 2022 |
Neuroprotective role of chloroquine via modulation of autophagy and neuroinflammation in MPTP-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Chloroquine; Disease Models, Anima | 2023 |
Neuroprotective effects of fermented tea in MPTP-induced Parkinson's disease mouse model via MAPK signaling-mediated regulation of inflammation and antioxidant activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Inflammation; Mice; Mice, Inbre | 2023 |
Investigating Therapeutic Effects of Indole Derivatives Targeting Inflammation and Oxidative Stress in Neurotoxin-Induced Cell and Mouse Models of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Disease Models, | 2023 |
Involvement of Abnormal p-α-syn Accumulation and TLR2-Mediated Inflammation of Schwann Cells in Enteric Autonomic Nerve Dysfunction of Parkinson's Disease: an Animal Model Study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Autonomic Pathways; Disease | 2023 |
Necrosulfonamide exerts neuroprotective effect by inhibiting necroptosis, neuroinflammation, and α-synuclein oligomerization in a subacute MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
Novel flavonoid 1,3,4-oxadiazole derivatives ameliorate MPTP-induced Parkinson's disease via Nrf2/NF-κB signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Disea | 2023 |
Casein Reactivates Dopaminergic Nerve Injury and Intestinal Inflammation with Disturbing Intestinal Microflora and Fecal Metabolites in a Convalescent Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caseins; Disease Models, Animal; Dopamine; Ga | 2023 |
Huperzine A injection ameliorates motor and cognitive abnormalities via regulating multiple pathways in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Cognition; Disease Mode | 2023 |
Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Blood | 2019 |
Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson's disease mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Disease Models, Animal; DNA Glyc | 2020 |
Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2020 |
Anti-neuroinflammatory effects of dimethylaminomylide (DMAMCL, i.e., ACT001) are associated with attenuating the NLRP3 inflammasome in MPTP-induced Parkinson disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Catalase; Circadian Rhythm; | 2020 |
BMAL1 regulation of microglia-mediated neuroinflammation in MPTP-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; ARNTL Transcription Factors; Disease Models, | 2020 |
Bruceine D elevates Nrf2 activation to restrain Parkinson's disease in mice through suppressing oxidative stress and inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2020 |
Eupatilin prevents behavioral deficits and dopaminergic neuron degeneration in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Astrocytes; Behavior, Animal; Dopa | 2020 |
Sodium Butyrate Exacerbates Parkinson's Disease by Aggravating Neuroinflammation and Colonic Inflammation in MPTP-Induced Mice Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Butyric Acid; Cell Line; Colon; C | 2020 |
LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Brain; Cell Line; Enh | 2020 |
Korean Red Ginseng Regulates Intestinal Tight Junction and Inflammation in the Colon of a Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Colon; Disease Models, Anima | 2020 |
2-Hydroxy-4-Methylbenzoic Anhydride Inhibits Neuroinflammation in Cellular and Experimental Animal Models of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Benzoates; Cell Surviva | 2020 |
NLRP3 Inflammasome Inhibition Prevents α-Synuclein Pathology by Relieving Autophagy Dysfunction in Chronic MPTP-Treated NLRP3 Knockout Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Autophagy; Corpus Striatum; | 2021 |
MPTP toxicity causes vocal, auditory, orientation and movement defects in the echolocation bat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Aromatic-L-Amino-Acid Decarboxylas | 2021 |
Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
Korean red ginseng suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced inflammation in the substantia nigra and colon.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colon; Disease Models, Animal; Dopaminergic N | 2021 |
Intragastric Administration of Casein Leads to Nigrostriatal Disease Progressed Accompanied with Persistent Nigrostriatal-Intestinal Inflammation Activited and Intestinal Microbiota-Metabolic Disorders Induced in MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caseins; Colon; Dopaminergic Neurons; Dysbios | 2021 |
Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzofurans; Body Weight; Disease Models, Ani | 2021 |
MicroRNA-93 Blocks Signal Transducers and Activator of Transcription 3 to Reduce Neuronal Damage in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cells, Cultured; Dopaminergic Neur | 2021 |
A New Tool to Study Parkinsonism in the Context of Aging: MPTP Intoxication in a Natural Model of Multimorbidity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2021 |
Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; CD8 Antigens; CD8-Positive T-Lymphocyt | 2021 |
A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Glucose; Body Weight; Brain; Calcium-Bi | 2017 |
TREM2 overexpression attenuates neuroinflammation and protects dopaminergic neurons in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adenoviridae; Animals; | 2018 |
The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Anti-Inflammatory Agent | 2018 |
Neural Stem Cell Grafts Promote Astroglia-Driven Neurorestoration in the Aged Parkinsonian Brain via Wnt/β-Catenin Signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Astrocytes; Brain; Cell Death; Cell Di | 2018 |
TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arginase; Cell Line; Cell Polarity; Cytokines | 2018 |
Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gait; Hindlimb; Homeo | 2018 |
2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Astrocytes; Behavior, Animal | 2018 |
PPARß/δ agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2019 |
JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Cells, Cultured; Cytokines; | 2018 |
Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Ente | 2018 |
Parkin targets NOD2 to regulate astrocyte endoplasmic reticulum stress and inflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Cells, Cultured; Cytokines; Endop | 2018 |
Calycosin attenuates MPTP-induced Parkinson's disease by suppressing the activation of TLR/NF-κB and MAPK pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Dopaminergic Neurons; Inflam | 2019 |
TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson's diseases in vivo model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cytokines; Disease Models, A | 2019 |
Aquaporin-4 deficiency reduces TGF-β1 in mouse midbrains and exacerbates pathology in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Aquaporin 4; Astrocytes; Cel | 2019 |
MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Autophagy; Cell Line; Cell Line, T | 2019 |
Anti-inflammatory Activity of Ursolic Acid in MPTP-Induced Parkinsonian Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antiparkinson Agent | 2019 |
Potentiating a non-neuronal cardiac cholinergic system reinforces the functional integrity of the blood brain barrier associated with systemic anti-inflammatory responses.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Animals; Astrocytes; Blood-Brain Barrie | 2019 |
Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adoptive Transfer; Animals; CD4-Positive T-Lymphocytes | 2013 |
Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Corpus Striatum; | 2014 |
Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopaminergic Neurons; Inflammation; Li | 2013 |
Anti-neuroinflammatory effects of DPTP, a novel synthetic clovamide derivative in in vitro and in vivo model of neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Line; Cells, Cultured; Disease Mo | 2015 |
Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-κB-dependent inflammation process in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Cell Line, Tumor; | 2015 |
Phytic acid attenuates inflammatory responses and the levels of NF-κB and p-ERK in MPTP-induced Parkinson's disease model of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Calcium-Binding Pro | 2015 |
Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2015 |
Chronic and progressive Parkinson's disease MPTP model in adult and aged mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Catecholamines; Chronic D | 2016 |
Design and evaluation of mucoadhesive microemulsion for neuroprotective effect of ibuprofen following intranasal route in the MPTP mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adhesives; Administration, Intranasal; Animals; Corpus | 2016 |
Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents; Di | 2016 |
Alteration of nuclear factor-kappaB pathway promote neuroinflammation depending on the functions of estrogen receptors in substantia nigra after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Calcium-Binding Proteins; Cell Co | 2016 |
Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Chronic Disease; Dis | 2016 |
The Isothiocyanate Isolated from Moringa oleifera Shows Potent Anti-Inflammatory Activity in the Treatment of Murine Subacute Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Biomarkers; Body We | 2017 |
Inhibitory effect of thiacremonone on MPTP-induced dopaminergic neurodegeneration through inhibition of p38 activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Astrocytes; Behavio | 2016 |
Puerarin prevents inflammation and apoptosis in the neurocytes of a murine Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Caspas | 2016 |
Injury-stimulated Sonic hedgehog expression in microglia contributes to neuroinflammatory response in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Disease Models, Animal; Hedg | 2017 |
Activin A Inhibits MPTP and LPS-Induced Increases in Inflammatory Cell Populations and Loss of Dopamine Neurons in the Mouse Midbrain In Vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Activins; Animals; Cell Survival; Disease Models, Anim | 2017 |
Rapamycin upregulates glutamate transporter and IL-6 expression in astrocytes in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Transport System X-AG; Animals; Astrocytes; | 2017 |
Defining "neuroinflammation".
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Bacterial Agents; Antibodies, Phospho-Sp | 2008 |
Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; CD4-Positive T-Lymphocytes; CD8-Positi | 2009 |
MPTP administration increases plasma levels of acute phase proteins in non-human primates (Macaca fascicularis).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute-Phase Proteins; Animals; C-Reactive Protein; Dop | 2009 |
Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Immunohistochemistry; Inflammation; Macaca fa | 2009 |
Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antidepressive Agents, Second-Generation; Blo | 2010 |
The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Astrocytoma; Blotting, Western; C | 2010 |
Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Corp | 2010 |
Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aquaporin 4; CD4 Antigens; Cells, Cultured; C | 2011 |
Low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor-κB reporter mice prior to loss of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Astrocytes; Cell Death; | 2011 |
Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Dopaminergic Neuron | 2012 |
Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cells, Cultured; Cerebral Cortex; | 2012 |
Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Crystallin B Chain; Animals; Astrocytes; Dopamin | 2013 |
Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Cytochrom | 2004 |
Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Blotting, Western; | 2004 |
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Disease Mo | 2005 |
Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; Animals; Astrocytes; C | 2006 |